pharmaphorum January 26, 2022
Johnson & Johnson has said the impending spin-off of its consumer health division won’t stop it from “forging ahead” with M&A deals to expand its other businesses including pharma and medical devices.
On a conference call to discuss the company’s fourth-quarter results, new chief executive Joaquin Duato said the focus will continue to be on “tuck-in” deals to help fill its R&D pipeline, but said he would also consider larger deals “if the situation is granted.”
The preference will be for small “new molecule, new device” assets on which J&J can apply its development, manufacturing, regulatory and commercial expertise, according to Duato.
Any future acquisitions will not have a bearing on its objective of reaching $60 billion in annual sales...
Today's Sponsors
Today's Sponsor